Jean Luc Raoul
Overview
Explore the profile of Jean Luc Raoul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
871
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Adhoute X, Penaranda G, Raoul J, Le Treut P, Bollon E, Hardwigsen J, et al.
World J Hepatol
. 2016 Jun;
8(17):703-15.
PMID: 27330679
Therapeutic management of hepatocellular carcinoma (HCC) is quite complex owing to the underlying cirrhosis and portal vein hypertension. Different scores or classification systems based on liver function and tumoral stages...
12.
Birnbaum D, Bertucci F, Finetti P, Adelaide J, Giovannini M, Turrini O, et al.
Cancer Genomics Proteomics
. 2016 Apr;
13(3):191-200.
PMID: 27107061
Background/aim: Individual molecular information might improve management of pancreatic adenocarcinoma. To identify actionable genes, at the transcriptional level, we investigated candidate genes that we had previously identified using array-comparative genomic...
13.
Adhoute X, Penaranda G, Raoul J, Bourliere M
Liver Int
. 2016 Jan;
36(9):1395-6.
PMID: 26778275
No abstract available.
14.
Pietrasz D, Marthey L, Wagner M, Blanc J, Laurent C, Turrini O, et al.
Ann Surg Oncol
. 2015 Aug;
22 Suppl 3:S1196-205.
PMID: 26271395
Purpose: In view of increased response rates and survivals in patients with metastatic pancreatic adenocarcinoma (PAC) with FOLFIRINOX, many centers proposed this regimen as induction chemotherapy for borderline (BR) or...
15.
Duconseil P, Gilabert M, Gayet O, Loncle C, Moutardier V, Turrini O, et al.
Am J Pathol
. 2015 Mar;
185(4):1022-32.
PMID: 25765988
A major impediment to the effective treatment of patients with pancreatic ductal adenocarcinoma (PDAC) is the molecular heterogeneity of this disease, which is reflected in an equally diverse pattern of...
16.
Adhoute X, Penaranda G, Raoul J, Bourliere M
J Hepatol
. 2015 Feb;
62(6):1442-3.
PMID: 25678389
No abstract available.
17.
A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor
Gayet O, Loncle C, Duconseil P, Gilabert M, Lopez M, Moutardier V, et al.
Oncotarget
. 2014 Dec;
6(2):746-54.
PMID: 25481873
Pancreatic Ductal Adenocarcinoma (PDAC) is a disease with a great heterogeneity in the response to treatments. To improve the responsiveness to treatments there are two different approaches, the first one...
18.
Adhoute X, Penaranda G, Naude S, Raoul J, Perrier H, Bayle O, et al.
J Hepatol
. 2014 Dec;
62(4):855-62.
PMID: 25463541
Background & Aims: Transarterial chemoembolization (TACE) is the standard of care for intermediate stage hepatocellular carcinoma (HCC) and it is the most commonly used treatment for HCC worldwide. However, no...
19.
Giovannini M, Caillol F, Poizat F, Bories E, Pesenti C, Monges G, et al.
Endosc Ultrasound
. 2014 Jun;
1(2):80-3.
PMID: 24949342
The primary goal of this study was to develop descriptive image interpretation criteria and a classification of endoscopic ultrasound-confocal microscopy (EUS-CM) findings in pancreatic masses and lymph nodes through a...
20.
Bolondi L, Burroughs A, Dufour J, Galle P, Mazzaferro V, Piscaglia F, et al.
Semin Liver Dis
. 2013 Feb;
32(4):348-59.
PMID: 23397536
The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly heterogeneous patient population and therefore poses unique challenges for therapeutic management, different from the early and advanced stages. Patients classified...